Skip to main content
NCBI home page
Clinical Cardiology logoLink to Clinical Cardiology
. 2010 Jan 8;33(1):4–9. doi: 10.1002/clc.20702

Dyslipidemia in the Elderly: Should it Be Treated?

Madhan Shanmugasundaram 1,✉, Steven J Rough 2, Joseph S Alpert 3
PMCID: PMC6653208  PMID: 20063295

Abstract

Elderly or older adults constitute a rapidly growing segment of the United States population, thus resulting in an increase in morbidity and mortality related to cardiovascular disease—an increase that is reaching epidemic proportions. Dyslipidemia is a well established risk factor for cardiovascular disease and is estimated to account for more than half of the global cases of coronary artery disease. Despite the increased prevalence of dyslipidemia in the older adult population, controversy persists regarding the benefits of treatment in this group. Epidemiologic studies have shown that dyslipidemia is often underdiagnosed and under treated in this population probably as a result of a paucity of evidence regarding the impact of treatment in delaying the progression of atherosclerotic disease, concerns involving increased likelihood of adverse events or drug interactions, or doubts regarding the cost effectiveness of lipid‐lowering therapy in older adults. In conclusion, despite the proven efficacy of lipid‐lowering therapy in decreasing cardiovascular morbidity and mortality, these therapies have been underutilized in older patients. Copyright © 2010 Wiley Periodicals, Inc.

Full Text

The Full Text of this article is available as a PDF (112.6 KB).

References

  • 1. Thom T, Haase N, Rosamond W, et al. Heart disease and stroke statistics—2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2006; 113(6): e85–e151. [DOI] [PubMed] [Google Scholar]
  • 2.Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285(19): 2486–2497. [DOI] [PubMed] [Google Scholar]
  • 3. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004; 110(2): 227–239. [DOI] [PubMed] [Google Scholar]
  • 4. Poehlman ET, Toth MJ, Bunyard LB, et al. Physiological predictors of increasing total and central adiposity in aging men and women. Arch Intern Med 1995; 155(22): 2443–2448. [PubMed] [Google Scholar]
  • 5. Sial S, Coggan AR, Carroll R, et al. Fat and carbohydrate metabolism during exercise in elderly and young subjects. Am J Physiol 1996; 271(6 Pt 1): E983–E989. [DOI] [PubMed] [Google Scholar]
  • 6. Wolfe RR, Klein S, Carraro F, Weber JM. Role of triglyceride‐fatty acid cycle in controlling fat metabolism in humans during and after exercise. Am J Physiol 1990; 258(2 Pt 1): E382–E389. [DOI] [PubMed] [Google Scholar]
  • 7. Boden G, Chen X, Ruiz J, et al. Mechanisms of fatty acid‐induced inhibition of glucose uptake. J Clin Invest 1994; 93(6): 2438–2446. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8. Miller GJ, Miller NE. Plasma‐high‐density‐lipoprotein concentration and development of ischaemic heart‐disease. Lancet 1975; 1(7897): 16–19. [DOI] [PubMed] [Google Scholar]
  • 9. Gordon T, Castelli WP, Hjortland MC, et al. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 1977; 62(5): 707–714. [DOI] [PubMed] [Google Scholar]
  • 10. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998; 279(20): 1615–1622. [DOI] [PubMed] [Google Scholar]
  • 11. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo‐controlled trial. Lancet 2004; 364(9435): 685–696. [DOI] [PubMed] [Google Scholar]
  • 12. Neil HA, DeMicco DA, Luo D, et al. Analysis of efficacy and safety in patients aged 65–75 years at randomization: Collaborative Atorvastatin Diabetes Study (CARDS). Diabetes Care 2006; 29(11): 2378–2384. [DOI] [PubMed] [Google Scholar]
  • 13. Lemaitre RN, Psaty BM, Heckbert SR, et al. Therapy with hydroxymethylglutaryl coenzyme a reductase inhibitors (statins) and associated risk of incident cardiovascular events in older adults: evidence from the Cardiovascular Health Study. Arch Intern Med 2002; 162(12): 1395–1400. [DOI] [PubMed] [Google Scholar]
  • 14. Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002; 360(9346): 1623–1630. [DOI] [PubMed] [Google Scholar]
  • 15. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C‐reactive protein. N Engl J Med 2008; 359(21): 2195–2207. [DOI] [PubMed] [Google Scholar]
  • 16. Miettinen TA, Pyorala K, Olsson AG, et al. Cholesterol‐lowering therapy in women and elderly patients with myocardial infarction or angina pectoris: findings from the Scandinavian Simvastatin Survival Study (4S). Circulation 1997; 96(12): 4211–4218. [DOI] [PubMed] [Google Scholar]
  • 17.Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high‐risk individuals: a randomised placebo‐controlled trial. Lancet 2002; 360(9326): 7–22. [DOI] [PubMed] [Google Scholar]
  • 18. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996; 335(14): 1001–1009. [DOI] [PubMed] [Google Scholar]
  • 19. Lewis SJ, Moye LA, Sacks FM, et al. Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the Cholesterol and Recurrent Events (CARE) trial. Ann Intern Med 1998; 129(9): 681–689. [DOI] [PubMed] [Google Scholar]
  • 20. Hunt D, Young P, Simes J, et al. Benefits of pravastatin on cardiovascular events and mortality in older patients with coronary heart disease are equal to or exceed those seen in younger patients: Results from the LIPID trial. Ann Intern Med 2001; 134(10): 931–940. [DOI] [PubMed] [Google Scholar]
  • 21. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long‐Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998; 339(19): 1349–1357. [DOI] [PubMed] [Google Scholar]
  • 22. Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 2001; 285(13): 1711–1718. [DOI] [PubMed] [Google Scholar]
  • 23. Olsson AG, Schwartz GG, Szarek M, et al. Effects of high‐dose atorvastatin in patients ≥ 65 years of age with acute coronary syndrome (from the myocardial ischemia reduction with aggressive cholesterol lowering [MIRACL] study). Am J Cardiol 2007; 99(5): 632–635. [DOI] [PubMed] [Google Scholar]
  • 24. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352(14): 1425–1435. [DOI] [PubMed] [Google Scholar]
  • 25. Wenger NK, Lewis SJ, Herrington DM, et al. Treating to New Targets Study Steering Committee and Investigators. Outcomes of using high‐ or low‐dose atorvastatin in patients 65 years of age or older with stable coronary heart disease. Ann Intern Med 2007; 147(1): 1–9. [DOI] [PubMed] [Google Scholar]
  • 26. Deedwania P, Stone PH, Bairey Merz CN, et al. Effects of intensive versus moderate lipid‐lowering therapy on myocardial ischemia in older patients with coronary heart disease: results of the Study Assessing Goals in the Elderly (SAGE). Circulation 2007; 115(6): 700–707. [DOI] [PubMed] [Google Scholar]
  • 27. Maroo BP, Lavie CJ, Milani RV. Efficacy and safety of intensive statin therapy in the elderly. Am J Geriatr Cardiol 2008; 17(2): 92–100. [PubMed] [Google Scholar]
  • 28. Dale KM, Coleman CI, Henyan NN, et al. Statins and cancer risk: a meta‐analysis. JAMA 2006; 295(1): 74–80. [DOI] [PubMed] [Google Scholar]
  • 29. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol‐lowering treatment: prospective meta‐analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet 2005; 366(9493): 1267–1278. [DOI] [PubMed] [Google Scholar]
  • 30. Bernick C, Katz R, Smith NL, et al. Statins and cognitive function in the elderly: the Cardiovascular Health Study. Neurology 2005; 65(9): 1388–1394. [DOI] [PubMed] [Google Scholar]
  • 31. Jick H, Zornberg GL, Jick SS, et al. Statins and the risk of dementia. Lancet 2000; 356(9242): 1627–1631. [DOI] [PubMed] [Google Scholar]
  • 32. Rockwood K, Kirkland S, Hogan DB, et al. Use of lipid‐lowering agents, indication bias, and the risk of dementia in community‐dwelling elderly people. Arch Neurol 2002; 59(2): 223–227. [DOI] [PubMed] [Google Scholar]
  • 33. Zandi PP, Sparks DL, Khachaturian AS, et al. Do statins reduce risk of incident dementia and Alzheimer disease? The Cache County Study. Arch Gen Psychiatry 2005; 62(2): 217–224. [DOI] [PubMed] [Google Scholar]
  • 34. Simons M, Keller P, De Strooper B, et al. Cholesterol depletion inhibits the generation of beta‐amyloid in hippocampal neurons. Proc Natl Acad Sci USA 1998; 95(11): 6460–6464. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35. Berge KG, Canner PL. Coronary drug project: experience with niacin. Coronary Drug Project Research Group. Eur J Clin Pharmacol 1991; 40(suppl):1 S49–S51. [PubMed] [Google Scholar]
  • 36. Goldbourt U, Behar S, Reicher‐Reiss H, et al. Rationale and design of a secondary prevention trial of increasing serum high‐density lipoprotein cholesterol and reducing triglycerides in patients with clinically manifest atherosclerotic heart disease (the Bezafibrate Infarction Prevention Trial). Am J Cardiol 1993; 71(11): 909–915. [DOI] [PubMed] [Google Scholar]
  • 37. Scott R, Best J, Forder P, et al. Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: baseline characteristics and short‐term effects of fenofibrate [ISRCTN64783481]. Cardiovasc Diabetol 2005; 4: 13. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38. Buse JB, Bigger JT, Byington RP, et al; ACCORD Study Group. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. Am J Cardiol 2007; 99(12A): 21i–33i. [DOI] [PubMed] [Google Scholar]
  • 39. Lipka L, Sager P, Strony J, et al. Efficacy and safety of coadministration of ezetimibe and statins in elderly patients with primary hypercholesterolaemia. Drugs Aging 2004; 21(15): 1025–1032. [DOI] [PubMed] [Google Scholar]
  • 40. Knoops KT, de Groot LC, Kromhout D, et al. Mediterranean diet, lifestyle factors, and 10‐year mortality in elderly European men and women: the HALE project. JAMA 2004; 292(12): 1433–1439. [DOI] [PubMed] [Google Scholar]
  • 41. Fletcher GF, Balady G, Blair SN, et al. Statement on exercise: benefits and recommendations for physical activity programs for all Americans. A statement for health professionals by the Committee on Exercise and Cardiac Rehabilitation of the Council on Clinical Cardiology, American Heart Association. Circulation 1996; 94(4): 857–862. [DOI] [PubMed] [Google Scholar]

Articles from Clinical Cardiology are provided here courtesy of Wiley

RESOURCES